BACKGROUND & AIMS:
Chronic infection with hepatitis C virus (HCV) has many hepatic and extrahepatic manifestations, measured by patient-reported outcomes (PROs). We measured changes in PROs during HCV treatment with recently developed pangenotypic regimens and from a sustained virologic response 12 weeks after treatment ended (SVR12).
METHODS:
We collected PRO data from 2 multi-center, blinded, international phase 3 trials of sofosbuvir, velpatasvir, and voxilaprevir, from 748 patients previously treated with direct-acting antivirals for chronic infection with HCV of any genotype (59% HCV genotype 1, 43% with compensated cirrhosis) (POLARIS-1 and POLARIS-4). The combination of sofosbuvir, velpatasvir, and voxilaprevir was given to 445 patients, the combination of sofosbuvir and velpatasvir to 151 patients, and placebo to 152 patients. Patients completed the SF-36, FACIT-F, CLDQ-HCV, and WPAI:SHP questionnaires at baseline, during treatment, and during the follow-up period.
RESULTS:
There was no difference in baseline clinical or demographic features or PRO scores among the groups (all P > .05). The group that received the combination of sofosbuvir, velpatasvir, and voxilaprevir had more gastrointestinal symptoms than the groups that received sofosbuvir and velpatasvir or placebo (P [ .0001). An SVR12 was achieved by 90.1% of patients who received sofosbuvir and velpatasvir vs 96.9% of patients who received sofosbuvir, velpatasvir, and voxilaprevir (P [ .0008). After 12 weeks of treatment, some PRO scores improved in both treatment groups (by 2.5 or by 9.1 points, on a 0-100 scale; P < .05) but not in the placebo group. All increases in PRO scores were sustained or increased after treatment ended (an increase of up to 11.1 points at 12 weeks after treatment and an increase of up to 16.6 points at 24 weeks after treatment ended) (P < .05 for all but 2 PROs). There were no differences in PROs between the sofosbuvir and velpatasvir group vs the sofosbuvir, velpatasvir, and voxilaprevir group (all P > .05). In multivariate analysis, after adjustment for clinical and demographic factors and baseline PRO scores, receiving treatment was associated with higher PROs scores than receiving placebo (beta as high as 5.1) (P < .05).
CONCLUSIONS:
In an analysis of data from 2 phase 3 clinical trials of patients with chronic HCV infection of any genotype, we found the combination of sofosbuvir, velpatasvir, with or without voxilaprevir, to increase PRO scores compared with placebo. These findings indicate the comprehensive benefit of these regimens during treatment and after SVR.
C hronic hepatitis C infection is now increasingly considered a systematic infection with clinical manifestations exhibited as liver disease and several extrahepatic diseases. [1] [2] [3] [4] In particular, hepatitis C virus (HCV) has clearly been associated with liver-related adverse outcomes, such as cirrhosis, hepatocellular carcinoma, and excessive liver-related mortality.
2,5-7 Additionally, HCV has nonliver clinical manifestations, such as mixed cryoglobulinemia, porphyria cutanea tarda, type 2 diabetes, chronic fatigue, and depression. 3, 4 In addition to its clinical impact, HCV infection also impairs patientreported outcomes (PROs), such as quality of life and work productivity. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] As a consequence of the spectrum of its outcomes, HCV infection is responsible for tremendous economic burden through direct and indirect costs, and also the loss of worker productivity. 9, 11, [24] [25] [26] [27] [28] [29] Over the past 5 years, treatment of chronic HCV infection has been revolutionized. Indeed, the field has moved from interferon-based regimens with high toxicity and low efficacy to interferon-free ribavirin-free directacting antiviral (DAA)-based regimens with more than 95% cure rates, minimal contraindications, and mild or no side effects. [30] [31] [32] Additionally, there is evidence that, unlike interferon and ribavirin, these regimens improve PROs during treatment and after achieving sustained virologic response (SVR). [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] The aim of this study was to assess changes in PRO scores seen during treatment and after achieving SVR with a newly developed pangenotypic regimen for HCV.
Methods
In this study, we used the PRO data collected from participants of POLARIS-1 (clinicaltrials.gov #NCT02607735) and POLARIS-4 (#NCT02639247) studies because those were similarly designed as multicenter multinational phase 3 clinical trials of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in DAA-experienced patients with chronic HCV of all genotypes. In POLARIS-1, patients with HCV genotype 1 were to be randomized 1:1 in a blinded manner, stratified by HCV genotype and cirrhosis, to receive either a fixed-dose combination of SOF/VEL/VOX (400/ 100/100 mg) or placebo once daily for 12 weeks; patients with other genotypes were assigned to receive the fixed-dose combination of SOF/VEL/VOX. In POLARIS-4, patients with HCV genotypes 1, 2, and 3 were randomized 1:1, stratified by HCV genotype and cirrhosis, to receive open-label SOF/VEL or SOF/VEL/ VOX for 12 weeks; those with other genotypes were assigned to receive SOF/VEL/VOX. In both trials, eligibility criteria included being 18 years of age or older, having no clinically significant illness or health condition other than chronic HCV infection, having no history of hepatic decompensation, and the absence of hepatitis B virus or human immunodeficiency virus coinfection. 30 The trials were conducted in the United States, Canada, Australia, New Zealand, Germany, France, and Great Britain in 2015-2017. Other details of the trials' design and safety and efficacy outcomes of both trials have been published. 30 In addition, using medical history collected at screening, we identified patients with pretreatment history of depression or mood disorders, clinically overt fatigue, anxiety or panic disorders, insomnia or sleep disorders, and type 2 diabetes mellitus. Treatment-related adverse events reported by the investigators were summarized by the body system or organ class.
Patient-Reported Outcomes
PROs were prospectively collected as exploratory endpoints in POLARIS-1 and POLARIS-4 trials. For the purpose of PRO collection, participants of both trials self-administered 4 PRO instruments, Short-Form-36 (SF-36), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Chronic Liver Disease Questionnaire-HCV Version (CLDQ-HCV), and Work Productivity Activity Index: Specific Health Problem (WPAI:SHP), [33] [34] [35] [36] [37] at baseline (the first day of treatment); at treatment week 4 and 12 visits; and at week 4, 12, and 24 follow-up visits. Patients who had received placebo did not have follow-up visits after post-treatment week 4.
Together, the 4 PRO instruments can be used to calculate 20 independent PRO domains, 5 summary scores, and 1 preference-based utility score (SF-6D). These PROs reflect various aspects of patients' daily well-being and health-related quality of life including physical health, fatigue, mental and emotional health, bodily pain, social functioning, and work productivity. [33] [34] [35] [36] [37] The use of these 4 PRO instruments in clinical trials in patients with HCV has been previously described. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] In all PRO domains, greater scores indicate better health except for the domains of WPAI:SHP in which greater scores indicate a greater impairment. For presentation purpose, we additionally transformed changes in PROs from their original scales to a universal 0-100 scale.
Statistical Analysis
Clinicodemographic parameters, the rates of adverse events by the body system or organ class, and baseline, on-treatment, and post-treatment PROs were summarized as number (percent) or mean AE standard deviation and then compared among the 3 treatment groups (patients who received SOF/VEL, SOF/VEL/VOX, and placebo) and other subgroups of interest using chi-square test for independence or Wilcoxon nonparametric test. Also, at all study time points, we calculated the changes (decrements or improvements) in the PRO scores with reference to patients' own baseline levels and used Wilcoxon signed rank test to identify significant changes. Only P values of .05 or less were considered potentially statistically significant.
The association of treatment received (active treatment vs placebo or SOF/VEL vs SOF/VEL/VOX) with PRO scores of patients with HCV was assessed in a series of multiple linear regression models. The models included adjustment for the baseline PRO levels and for demographic and clinical PRO predictors; those were location (United States vs non United States), age, gender, race, history of comorbidities mentioned previously, the presence of compensated cirrhosis, body mass index, and history of type 2 diabetes.
All analyses were run using SAS version 9.4 (SAS Institute, Cary, North Carolina). The study was separately approved by each site's institutional review board.
Results
There were 748 DAA-experienced patients with HCV enrolled in POLARIS-1 and -4. Of these, 151 received SOF/VEL, 445 received SOF/VEL/VOX, and 152 received placebo. The study cohort included 59% with HCV genotype 1 and 43% with compensated cirrhosis. There were no significant differences in baseline clinicodemographic characteristics between patients receiving SOF/ VEL and SOF/VEL/VOX (all P > .05). However, by design, patients receiving placebo were nearly all genotype 1; they also had had less cirrhosis, and were primarily enrolled in the United States (Table 1) . Similarly, there was no significant difference in baseline PRO scores between patients assigned to receive different treatment regimens (all P > .05) (Supplementary Table 1) .
During treatment, patients receiving SOF/VEL/VOX had significantly more gastrointestinal symptoms (the most common were nausea and diarrhea) than patients receiving SOF/VEL or placebo (P ¼ .0001). The rate of musculoskeletal symptoms (the most common was arthralgia) was also slightly higher in the SOF/VEL/VOX arm compared with SOF/VEL or placebo (P ¼ .04). All other treatment-related adverse events were observed similarly in the 2 active treatment arms and the placebo arm ( Table 2 ). The SVR-12 rates were 90.1% in SOF/VEL and 96.9% in SOF/VEL/VOX (P ¼ .0008) ( Table 2) .
Patient-Reported Outcomes
The completion rate for the PRO instruments was 96%-98% at different time points. After treatment initiation (Week 4), there was moderate improvement in some PRO domains in patients receiving active treatment (P < .05 for general health, social functioning, and mental health of SF-36, emotional well-being of FACIT-F, and all but one domain of CLDQ-HCV; the average magnitude of improvement was from þ1.6 to þ7.7 points on a 0-100 PRO scale); the only statistically significant PRO decrement was in absenteeism of WPAI:SHP in the SOF/VEL/ VOX arm (on average, -2.7 points; P ¼ .0017). However, there was no PRO improvement observed in the placebo arm except for the worry domain of CLDQ-HCV, which improved by, on average, þ4.7 points (P < .0001); all other 1-sided P > .05.
By the end of 12-week-long treatment, the same PRO domains continued to improve in patients treated with SOF/VEL or SOF/VEL/VOX (P < .05 for general health of SF-36, emotional well-being of FACIT-F, and the same domains of CLDQ-HCV; the average magnitude of improvement ranged from þ1.5 to þ9.1 points) ( Figure 1 ). In contrast, in the placebo arm, the improvement in the only improving domain of worry decreased to the average of þ2.5 points (P ¼ .03), whereas all other PROs remained at their baseline levels (all P > .05) (Figure 2A, Supplementary Figure 1A) . There was no difference in treatment-emergent PRO improvements between the 2 active treatment regimens of SOF/VEL and SOF/VEL/VOX (all P > .05).
After treatment cessation (post-treatment week 4), PRO improvements in patients who had cleared their infection with SOF/VEL or SOF/VEL/VOX became more prominent: P < .05 for all but 4 PRO scores, and the average magnitude was up to þ9.3 points on a 0-100 scale. However, similarly to the on-treatment time points, patients who completed placebo treatment continued to remain at their baseline PRO levels (all P > .05 except for worry of CLDQ-HCV) ( Figure 2B, Supplementary Figure 1B) .
Later in follow-up, all PRO improvements sustained or increased in patients with SVR-12 ( Figure 3 , Supplementary  Figure 2 ): up to þ11.1 points by post-treatment week 12, up to þ16.6 by post-treatment week 24; P < .05 for all but 2 PROs (social well-being of FACIT-F and absenteeism of WPAI:SHP). Again, there was no statistically significant difference between the SOF/VEL and SOF/VEL/VOX arms at any post-treatment time point (all P > .05).
Because there was some imbalance in the prevalence of cirrhosis between the treatment regimen groups, we additionally compared the end of treatment and posttreatment PRO changes between patients with and without cirrhosis receiving active treatment (n ¼ 274 vs 322). By the end of treatment, patients with cirrhosis experienced greater improvements in mental health of SF-36, fatigue scale of FACIT-F, and emotional and total score of CLDQ-HCV in comparison with subjects without cirrhosis (P .05), whereas all other PRO improvements were similar (Supplementary Figure 3A) . By SVR-12, all PRO improvements became similar between patients with and without cirrhosis (all P > .08). Furthermore, there was no difference in treatment-emergent or posttreatment PRO changes among patients enrolled from different countries (United States, n ¼ 323; France, n ¼ 101; Canada, n ¼ 66; other, n ¼ 106): despite substantial baseline differences, all P > .06. However, patients who had low baseline PRO scores (total CLDQ-HCV score in the lowest quartile <4.5; n ¼ 151 out of 583 with baseline data) experienced substantially more prominent end of treatment and post-treatment PRO improvements in comparison with those who had moderate or no PRO impairment at baseline (P < .05 for 23 out 26 studied PROs) (Supplementary Figure 3B) .
In multivariate analysis, independent predictors of baseline PRO impairment were, expectedly, the presence of comorbidities and cirrhosis. Additionally, patients enrolled in the United States had generally higher baseline PRO scores (Supplementary Table 2 ). During treatment, after adjustment for other PRO predictors (summarized in Supplementary Table 3 ) and baseline PRO levels, receiving active treatment rather than placebo was associated with having greater scores in some summary PROs (beta up to þ3.8 points, P ¼ .0016 for CLDQ-HCV) ( Figure 4A ). Furthermore, similarly to the univariate analysis presented previously, that positive association became substantially more prominent soon after treatment cessation: betas up to þ5.1 points ( Figure 4B ). In an additional round of multivariate analysis that involved patients receiving active treatment only, no association of a specific treatment regimen (SOF/VEL vs SOF/VEL/VOX) with any of the studied PROs was found (all P > .05).
Discussion
This is an extensive evaluation of PROs during and after treatment with 2 pangenotypic regimens for HCV. Our data clearly show that both regimens improve several PRO scores shortly after initiation of treatment. This improvement in PROs persisted throughout treatment and was even more considerable after achieving SVR-12. Moreover, the gains in PROs were not only sustained 12 weeks post-treatment but continued to further improve by Week 24 of follow-up. We believe that initial gains in PROs are related to viral suppression that can occur with both regimens. Indeed, no similar improvement was seen in subjects who received placebo in a blinded fashion. In addition, unlike previously studied interferon þ ribavirin-containing and interferonfree ribavirin-containing regimens, which resulted in decrements in PROs during treatment and weeks after treatment cessation, 18, 22 no treatment-emergent PRO decrements were observed in actively treated patients in this study. Furthermore, presented PRO gains were similar to those reported for other all-oral interferonand ribavirin-free regimens regardless of their duration. 8, 15, 16, 20, 21, 23 This suggests that patients' experience was not adversely affected by the side effects of the studied regimens and supports excellent tolerability of these regimens for HCV treatment.
In addition to the PRO benefit during treatment, the data clearly show that achieving SVR leads to sustainable gains in PROs, again consistent with previous reports for other DAA-based regimens. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] The magnitudes of post-SVR PRO improvements suggest their clinical relevance because most PROs increased by more than 3%-5% of a PRO range size, which is believed to be the minimal clinically important difference in PROs. 38, 39 Furthermore, such improvements are comparable with longterm improvements in PRO scores observed in patients who had cardiac bypass surgery for their coronary artery disease or patients with rheumatoid arthritis after 24 weeks of treatment with methotrexate. 40, 41 Accompanied by high efficacy of SOF/VEL AE VOX regimens, these PRO data provide support to the comprehensive benefit (to include clinical, or SVR, and patients' experience, or PROs) of these new regimens for HCV-infected patients.
Finally, we have confirmed that the presence of cirrhosis, fatigue, and psychiatric comorbidities contributes to impaired PROs in patients with HCV; this is consistent with similar findings from prior studies. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Although the exact causes of the observed association of location with baseline PROs are unclear, this is also consistent with prior reports on the contribution of cultural and ethnic factors to various PRO measures. 42, 43 Nevertheless, the sociodemographic reasons for this difference requires future investigation. Furthermore, our multivariate analysis clearly shows that receiving active treatment with SOF/VEL or SOF/VEL/VOX is independently and similarly associated with improvement of PROs during treatment and in post-treatment follow-up. It is important to note, however, that other major predictors of greater on-treatment and posttreatment PRO gains were factors associated with lower baseline scores, such as history of depression, anxiety, and clinically overt fatigue, suggesting that these conditions, potentially associated with the extrahepatic manifestations of HCV, may also potentially resolve with virologic clearance; further prospectively designed studies are needed to confirm this hypothesis.
The main limitation of this study is the setting where PRO data were collected. Given that the PRO improvements were documented in the clinical trials setting, similar data from real-world clinical practices are needed; this issue applies both to clinical outcomes and PROs.
Other limitations include open-label design of POLARIS-4, which might have affected PROs in participants; limited follow-up duration; and the lack of data on other potentially important PRO predictors, such as patients' education, family status, and other socioeconomic parameters.
In summary, our study assessed the effect of 2 anti-HCV regimens, SOF/VEL and SOF/VEL/VOX, on PRO scores. The data are supportive of the comprehensive benefit of the new all-oral pangenotypic regimens for patients infected with HCV who had failed another DAAbased regimen and might have been left with no treatment options otherwise.
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